Middle East Pharmaceutical Industries Co. (4016.SR)
SAR 131.6
(0.3%)
SAR 131.6
(0.3%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 338.43 Million SAR | 11.82% |
| 2022 | 302.66 Million SAR | 5.38% |
| 2021 | 287.22 Million SAR | -4.79% |
| 2020 | 301.66 Million SAR | 29.97% |
| 2019 | 232.09 Million SAR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 101.13 Million SAR | 33.38% |
| 2024 Q1 | 75.82 Million SAR | -20.16% |
| 2023 Q4 | 94.96 Million SAR | 0.0% |
| 2023 Q3 | 94.96 Million SAR | 1.79% |
| 2023 FY | 338.43 Million SAR | 11.82% |
| 2023 Q2 | 93.29 Million SAR | 68.92% |
| 2023 Q1 | 55.22 Million SAR | -34.94% |
| 2022 Q1 | 66.44 Million SAR | 0.0% |
| 2022 FY | 302.66 Million SAR | 5.38% |
| 2022 Q4 | 84.88 Million SAR | 0.0% |
| 2022 Q2 | 83.22 Million SAR | 25.25% |
| 2022 Q3 | 84.88 Million SAR | 1.99% |
| 2021 FY | 287.22 Million SAR | -4.79% |
| 2020 FY | 301.66 Million SAR | 29.97% |
| 2019 FY | 232.09 Million SAR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Al-Dawaa Medical Services Company | 5.74 Billion SAR | 94.105% |
| Nahdi Medical Company | 8.71 Billion SAR | 96.116% |
| Al-Razi Medical Co. | 61.33 Million SAR | -451.799% |
| Almujtama Alraida Medical Co. | 407.73 Million SAR | 16.996% |